CME Group Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2022 Annual Meeting of Shareholders held on May 4, 2022. The record date for the meeting was March 7, 2022, with 359,422,597 shares of Class A and Class B common stock issued and outstanding. The filing was submitted on May 6, 2022.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Shareholder participation was significant, with 297,860,848 shares (82.87% of issued and outstanding) present at the meeting. Key voting outcomes include:
- Director Elections (Class A & B): All seventeen Equity Director nominees were elected.
- Independent Auditor: The appointment of Ernst & Young LLP for 2022 was ratified.
- Executive Compensation (Say-on-Pay): The advisory vote on executive compensation was not approved, with 211,462,766 votes against versus 64,176,239 votes for.
- Stock Plans: Proposals to approve the Amended and Restated Omnibus Stock Plan, Director Stock Plan, and Employee Stock Purchase Plan were all approved.
- Class B Director Elections:
- Class B-1: No quorum was achieved; current directors (William W. Hobert, Patrick J. Mulchrone, Robert J. Tierney Jr.) will serve as "holdover" directors.
- Class B-2: Michael G. Dennis and Patrick W. Maloney were elected.
- Class B-3: No quorum was achieved; Elizabeth A. Cook will serve as a "holdover" director.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary, or specific risk factors beyond the procedural note regarding holdover directors due to lack of quorum in certain Class B elections.
Investor Verification Checklist
- Verify the rationale and potential impact of the failed "Say-on-Pay" vote (approx. 76% of votes cast were against).
- Confirm the status of the "holdover" directors for Class B-1 and B-3 and the timeline for their re-election.
- Review the specific terms of the newly approved stock plans (Omnibus, Director, and Employee Purchase) for dilution implications.
- Check subsequent filings for management's response to the executive compensation vote rejection.